Showing 1 - 10 of 13,972
recent investment disputes concerning pharmaceuticals. The underlying assumptions of this article are that adjudication is a …
Persistent link: https://www.econbiz.de/10012827492
With the ongoing trade normalisation process between India and Pakistan, opportunities to integrate have opened up between both countries. The pharmaceutical sector is crucial to health issues in developing economies and would be an ideal segment to focus on in improving trade relations between...
Persistent link: https://www.econbiz.de/10010404687
Persistent link: https://www.econbiz.de/10010425136
This chapter discusses whether foreign investors, specifically pharmaceutical companies, could challenge India's regulatory measures that impact their patents under India's BITs. More specifically, the paper will focus on whether regulatory measures such as compulsory licensing of pharmaceutical...
Persistent link: https://www.econbiz.de/10012959457
India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs)...
Persistent link: https://www.econbiz.de/10012711295
The economic literature reveals that the relationship between patents and Foreign Direct Investments (FDI) depends on industries and countries’ features. Our research considers the pharmaceutical industry in China. This choice stems from a contradictory observation: China is known for its...
Persistent link: https://www.econbiz.de/10012794273
Persistent link: https://www.econbiz.de/10012112492
Persistent link: https://www.econbiz.de/10011857537
Persistent link: https://www.econbiz.de/10011643971